CD8A and COVID-19: These observations suggest that COVID-19 vaccines, at least partially such as BNT162b2, can effectively induce rapid, robust and long-lasting immunodominant S protein epitope-specific CD4+ and CD8+ T cell responses that play a critical anti-COVID-19 role.